The National Institute for Health and Care Excellence (NICE) has today
published its Final Appraisal Determination on the use of dimethyl fumarate
(Skilarence) for severe psoriasis in England and Wales.
Dimethyl fumarate (Skilarence)
is recommended to treat severe psoriasis, where people have not had adequate
results from conventional systemic treatments, or cannot take them.
with psoriasis may be aware of a similar treatment, known as Fumaderm or
Fumaric Acid Esters. This is a German treatment that is not licensed in the UK,
but has sometimes been prescribed on a case-by-case basis. Dimethyl fumarate (Skilarence)
is licensed in the UK, and uses the main active ingredient from Fumaderm. This,
along with today’s NICE recommendation, should make fumaric acid ester
treatment more accessible to people with psoriasis in the UK.
We will be
publishing more information on dimethyl fumarate (Skilarence) for psoriasis
soon. In the meantime, please get in touch with us if you have any questions.